XIth Paterson Symposium: Anti-Tumour Effector Mechanisms by Moore, M.
Br. J. Cancer (1977) 35, 378
XIth PATERSON SYMPOSIUM
ANTI-TUMOUR EFFECTOR MECHANISMS
Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX
19-21 September 1976
SYNOPSIS OF PAPERS
The XIth Paterson Symposium was conceived with the objective of discussing
some areas of current activity in the field of tumour immunology. The theme
" Anti-tumour Effector Mechanisms " was adopted so as to focus attention on the
relationship of contemporary research on the in vitro characterization of potential
effector cells and antibodies to the problem of in vivo host resistance against experi-
mental and human neoplasms. To this end, the number of topics discussed was
restricted and the following is a brief synopsis.
A. J. S. DAVIES (Institute for Cancer
Research, London) suggested that attitudes
toward the pursuit oftumour immunology, as
of other biomedical sciences, were subject to
various pressures which were not without
considerable influence on the quality of
research. The tumour immunologist's dilem-
ma, in particular, arises from the professional
necessity topracticegood fundamental science
and the frequently opposing pressure for
prompt clinical application. The discipline
could be envisaged as the compound of two
mysteries: tumour induction and immune
response. The concept of the immune
response as an acceptance mechanism, as
recently advocated by Prehn, was more prob-
able than the more conventional view of
immunosurveillance, since the induction of
tumours under controlled laboratory condi-
tions had generally failed to provide suppor-
tive evidence for the immunosurveillance
hypothesis. On cytotoxic cells, Professor
Davies warned against uncritical extrapola-
tion of data acquired in vitro to the in vivo
situation. Specificity studies, particularly in
man, had been disappointing, and might
reflect interactions between cell membranes
rather than immune events.
The paper by Eva Klein (Karolinska
Institute, Stockholm) was the first of several
which discussed the activity of normal killer
(NK) cells against various in vitro targets.
NK function was assayed using a Moloney-
virus-induced lymphoma cell line kept in
culture (YAC) wrhich is exquisitely sensitive to
NK cells in vitro. NK function varies in the
different mouse strains. Certain of these
(e.g. A, which is syngeneic with YAC) are
devoid ofactivity, wAhilst others (e.g. CBA) are
highly active. The reactivity of F1 hybrids
reflects that of the active parental strain.
Comparison of tumour takes of a low number
of transplanted YAC cells in various strain
combinations, each of which was semi-
syngeneic with the A strain, provided evi-
dence of a defensive in vivo role for NK cells.
The target antigen could not be identified
with virus-determined cell-surface antigens
nor with viral components expressed on the
plasma membrane. Spleens of tumour-bear-
ing mice, including those carrying a human
lymphoblastoid cell line, revealed a markedly
decreased activity. NK cells could be isolat-
ed from progressor MSV sarcomas in A strain
mice.
B. M. Vose (Paterson Laboratories,
Christie Hospital and Holt Radium Institute)
discussed thephenomenon ofspontaneous cell-
mediated cytotoxicity (SCMC) in the context
ofhumanallogeneic microcytotoxicity testing.
Using the conventional visual microcyto-
toxicity assay, it was demonstrated that
human foetal lung cells were susceptible to
more than one effector-cell type present in the
peripheral blood of both normal subjects and
cancer patients. Attempts were made to
identify cytotoxic cells present in effector-cell
preparations, following removal of granulo-
cytes. Abrogation of cytotoxicity by carra-
geenan suggested a role for cells of the mono-ANTI-TUMOUR EFFECTOR MECHANISMS
cyte series. However, the presence of cyto-
toxic effectors in eluates from nylon and IgG-
anti-IgG columns from which monocytic cells
hadbeenvirtuallyexcluded,providedevidence
ofSCMCinnon-T lymphocytes. The activity
of these cells was relatively uninfluenced by
pre-treatment with heat-aggregated human y
globulin under conditions known to inhibit
K-cell function.
The system ofH. H. Peter (Department of
Clinical Immunology, Med. Hochschule Post-
fach, Hannover, West Germany) differed
from that of Dr Vose in using cells derived
from human malignant melanoma (JGR3) as
targets, and a 51Cr-release assay in the
identification of effector cells mediating
SCMC. In this study, SCMC closely paral-
leled antibody-dependent cellularcytotoxicity
(ADCC). In both assays, highest cytotoxic
activities were obtained with lymphocyte
preparations depleted of T cells and mono-
nuclear phagocytes. Passage ofeffector cells
through IgG-anti-IgG columns strongly de-
creased SCMC and ADCC activities, as did
also preincubation in aggregated IgG. De-
pletion of Fc- and C3-receptor-carrying
lymphocytes by rosetting techniques, dimin-
ished both ADCC and SCMC activity, sug-
gesting that the effector cells of the SCMC
reaction are related to the K cell known to
mediate lysis ofantibody-sensitized nucleated
target cells. SCMC effector cells were pre-
sent in the blood of normal individuals, as
well as melanoma patients in whom the
activity waned with progressive disease.
Evidence was presented that SCMC, although
mediated by the same group of " null "
lymphocytes as those responsible for the
K-cell effect, represents a complex pheno-
menon involving the co-operation ofdifferent
cell types and the production oflymphokines.
G. D. Bonnard (Laboratory of Immuno-
diagnosis, National Cancer Institute, Beth-
esda, Maryland, U.S.A.) challenged the
characterization of the NK cell as a non-T
cell with Fc and complement receptors.
Using a 4-h 51Cr-release assay against the
myeloid cell line K-562, it was shown thatthe
majority of effector cells in this system lack
the complement receptor, but are Fc+, and
thus very similar to the K cells active in
ADCC reactions. Moreover, both NK and K
cells bind sheep red blood cells (SRBC) at
4°C, a property which raises the possibility
that they belong to an Fc+ T-cell subpopula-
tion. NK and K-cell activity could be
generated in cultures of lymphocytes, parti-
cularly when done in foetal bovine serum, or
in the presence ofmitomycin-C-treated K-562
cells. The mechanism ofkilling ofNK and K
cells was somewhat different: the former were
unaffected by protein A from S. aureus which
binds selectively to the Fc portion ofIgG, and
significantly abrogates the K-cell effect,
whereas trypsin abrogated NK function,
leaving K-cell activity intact.
N. A. Mitchison (Department of Zoology,
University College, London) advanced the
view that, notwithstanding the anti-tumour
activity associated with NK cells and macro-
phages or their products, the future oftumour
immunology is likely to depend on the
manipulation and control of T-cell responses
to tumour-associated antigens. Their ap-
parent absence from some tumours reflected,
in his view, limitations in available methods
of detection. Adopting Gross-virus-induced
tumours in rats as a model system, Professor
Mitchison gave a comprehensive description
of the biochemically defined antigens of
murine leukaemia viruses (gp 70, p 30, p 15,
p 12 and p 10). The relationship ofthe viral
proteins to viral genomes was discussed in
some detail. For MLV, 4 complementation
groups were described: gag, pol, end and onc.
Attention focused particularly on those genes
(end and gag) controlling expression of viral
proteins at the surface of infected cells. A
major translation product ofthe gag gene was
described as a precursor polyprotein (mol. wt.
_105 dalton) the fate of which was either
extensive cleavage into smaller units (p 30,
p 15, p 12, p 10) or glycosylation to produce a
cell surface entity (mol. wt. -84,000 dalton)
carrying the determinant(s) previously known
as GCSA. Isolation of p 84 glycosylated
protein from lectin columns affords an inter-
esting system for studies of the blocking of
T-cell reactivity. In a variety of systems in
which weak antigens have been studied (e.g.
sex antigen, non-H-2 antigens, MLV-coded
cell-surface antigens) the activity of T cells
could be boosted in vitro by a factor of 102 to
103. Common features of these systems are
additive (mercaptoethanol) and medium
(RPMI 1640) dependence; maintenance by
restimulation in long-term cell lines; and
activity in adoptive-transfer tests. There
are problems of specificity, however, in that
the reactivity ofboosted cells does not match
that of non-boosted cells. These in vitro
systems are likely to provide information
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about blocking and stimulating configurations
of antigens at the cell surface.
A. C. Allison (Clinical Research Centre,
Harrow) added another mechanism by which
the immune system can kill or inhibit tumour
cells: viz. the action of the complement
cleavage product C3a which was shown to be
lytic for various transformed cells of human
and murine origin. All the tumour cell types
were lysed by low concentrations of C3a (1 to
10 ,tg/ml), but normal human lymphocytes
were relatively resistant. No lysis was
achieved by C3 or C3b. The generation of
C3a was envisaged to occur via the classical or
alternative pathways of complement activa-
tion, or through enzymatic cleavage of C3 by
products ofactivated macrophages. Tumour
cells release proteinases, including plasmino-
gen activator, and the active enzyme pro-
duced, plasmin, cleaves C3, with liberation of
C3a. There is thus the possibility that C3a
plays a role in immunity against tumour cells,
including that mediated by macrophages.
However, the mechanism by which C3a
accomplishes lysis is presently unknown.
In the first of a series of papers on the in
situ expression of immunity against experi-
mental tumours, I. P. Witz (Department of
Microbiology, Tel Aviv University, Israel)
stated that there is no a priori certainty that
immune components which act in vitro, taken
from sites distant from the tumour, actually
arrive at the tumour and function there;
and furthermore, the microenvironment of
tumours differs from that of normal tissues
and the laboratory " test-tube " in which
such interactions are most frequently studied.
However, it was apparent from studies in at
least onetumour-host systemthattumoursare
coated in vivo with potentially cytotoxic
antibodies. The mechanism by which tu-
mour cells escape lysis may be attributable to
complement deficiency or to some inadequate
arrangement ofantibody molecules at the cell
surface. Eluates from such tumours grown
in vivo contain antibodies with activity
directed against tumour antigens, and can be
shown to suppress tumour growth in vivo.
Tumour cells of non-lymphoid origin possess
receptors in vivo for immune complexes which
are apparently identical with Fc receptors,
though these may be lost on in vitro cultiva-
tion. These receptors could be blocked in
vivo and in vitro by specific anti-tumour anti-
bodies. In addition, host cells residing in
various tumours express Fc receptors in vivo
and in vitro and this accounts, in part, for the
presence of unrelated immunoglobulins in
tumours grown in vivo.
Several speakers contributed data on the
in situ expression of cellular host responses
against a variety of experimental neoplasms.
R. Evans (Division of Tumour Immunology,
Institute for Cancer Research, London)
described the effects of whole-body irradia-
tion (400 rad) and azathioprine treatment on
the FS6 fibrosarcoma in C57BL mice. In
this system, initial tumour growth was slower
in pre-irradiated hosts than in unirradiated
controls, and this was paralleled by virtual
absence of macrophage infiltration, an obser-
vation suggestingthatmacrophagesmayactu-
ally stimulate tumour growth. The influence
of azathioprine on macrophage infiltration
proved to be critically dependent on the time
of administration relative to that of tumour
implantation. Given concurrently on one
day before, the macrophage content of the
ensuing tumour was depressed, but one day
after, the drug was without effect. This find-
ing suggested that the initiation of the
immune response, reflected by the macro-
phage infiltration of the tumour, takes place
very rapidly after tumour implantation.
R. S. Kerbel (Department of Pathology,
Queen's University, Kingston, Ontario,
Canada) gave a critical evaluation of Fc-
receptor-bearing cells as a reliable marker for
estimation of lymphoreticular cell infiltration
of murine solid tumours of epithelial and
mesenchymal origin. Tests on parental tu-
mours derived from cultured cells, in F1
hybrid mice, revealed a very close correlation
between the respective proportions of infil-
trating host cells, as assessed by cytotoxic
treatment with an anti-H-2 serum specific for
the hosts' H-2 haplotype, and formation of
EA (Fc) rosettes. The infiltrating population
consisted predominantly of " activated "
macrophages and/or B lymphocytes; Fc- T
cells were present to a much more limited
extent. Primary and serially transplanted
chemically-induced sarcomas contained con-
sistently more host Fc+ cells (30-60%) than
spontaneously arising mammary carcinomas
(10-20%).
J. S. Haskill (Medical University of South
Carolina, Charleston, South Carolina, U.S.A.)
described in detail the complex series ofinter-
actions which occur in situ against the spon-
taneous mammary carcinoma T1699, which
may regress or progress in vivo, depending on
380ANTI-TUMOUR EFFECTOR MECHANISMS
the site of inoculation. He showed that the
in situ response depends on delayed hyper-
sensitivity, humoral antibody and the locali-
zation of Fc+ effector monocytes within the
tumour mass. The effector cells could not be
detected outside the tumour, although anti-
body with specificity for T1699 was present in
serum. In vitro colony-inhibition assays and
blockingstudieswithIgG2aggregatesstrongly
implicated serum-dependent macrophage-
mediated tumour-growth inhibition as the
primary anti-tumour response to this tumour
in vivo. Differences in in situ responses
between progressors and regressors appeared
to be quantitative rather than qualitative.
S. Russell (Department of Immuno-
pathology, Scripps Clinic and Research
Foundation, La Jolla, California, U.S.A.)
presented a complementary study on the
enumeration and functional capacity of
inflammatory cells recovered from either
regressing or progressing tumours indiuced by
injection of the Moloney sarcoma cell line,
MSC. Progressor and regressor tumours dis-
played differences, not only in the distribu-
tion of inflammatory cells at the site of the
tumour, but also in the functional capabilities
of the recovered populations. In regressing
tumours there was a preponderance of infil-
trating Tlymphocytes and some macrophages
which, histologically, were present within the
tumour matrix; the T cells could be recovered
in highly purified form and shown to be speci-
cally cytotoxic for MSC cells in vitro. By
contrast, in progressing tumours the mono-
nuclear cells were essentially confined to the
periphery of the neoplasms and, at the times
examined, exhibited less cytotoxic activity
in vitro than those recovered from regressors.
Suzanne Eccles (Chester Beatty Research
Institute, Sutton, Surrey) presented evidence
that the differing incidence of metastases
amongrattumoursisgovernedbytheimmune
responses ofthe host, and that animals which
do not normally develop overt metastases
may harbour " dormant " tumour cells with
the propensity to grow progressively if the
immunological restraint is removed. T-cell
depletion, during tumour growth or after
tumour excision, results in an increase in
metastases, suggesting the impairment of'
specific immune responses. However, since
thetumourswhichnormallyrarelymetastasize
induce a marked mono-cytosis and macro-
phage infiltration into the tumour mass
(which is reduced in T-cell-deprived hosts),
cells of the monocyte-macrophage series are
also implicated in the prevention of meta-
stases. In this system bacterial adjuvants
werereportedtoexertlittle anti-tumour effect
on " dormant " tumour cells.
Papers of a more clinical orientation were
concerned with the evaluation of specific and
non-specific immunity in cancer patients.
P. Hersey (KanematsuMemorialInstitute,
Sydney Hospital, Australia) reported that
antigens of potential biological importance
could be defined on human malignant mela-
noma cells, using a leucocyte-dependent anti-
body (LDA) assay and sera from selected
melanoma patients. Whilst extensive cross-
reactivity between different melanomas was
demonstrable, the overall pattern was one of
marked heterogeneity, andthis was confirmed
by cross-absorption studies. Evidence was
presented that some ofthese antigens were of
oncofoetal type, and that sensitization in vivo
was beneficial in malignant melanoma pati-
ents, inthat the death ratefromthisdiseasein
femaleswhohadpreviouslybeenpregnantwas
significantly lower than age-matched controls
with the disease who had never been preg-
nant. Dr Hersey suggested that other
clinical phenomena associated with this
disease (e.g. concurrent waxing and waning of
tumour deposits) might be attributable to
changes in the antigenicity ofmelanoma cells.
125I-labelled anti-melanoma antibodies
were preferentially localized in melanoma
nodules, compared with 131I-labelled non-
melanoma antibodies. LDA activity was
detectedinthe IgGfraction ofserafrommany
melanoma patients, even when no such
activity was present in the unfractionated
sera from the same subjects. The blocking
activity possessed partial affinity for the
melanoma target cells, and material with
comparable activity could also be recovered
from melanoma sera by dissociation at low
pH. Chromatographic separation of serum
samples revealed that both high- and low-
mol. wt. inhibitory factors are involved, the
latter probably comprising tumour antigen.
G. M. Taylor (Department Medical Genet-
ics, St Marys Hospital, Manchester) described
studies on cell-mediated cytotoxicity (CMC)
in acute myeloid leukaemia (AML), which
had shown that preimmunization of the
patient with allogeneic leukaemic cells,
followed by stimulation of patients lympho-
cytes in vitro with the same allogeneic leu-
kaemic cells, was a prerequisite for the
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demonstration of cell-mediated cytotoxicity.
Dr Taylor described studies to determine the
specificity of CMC induced by various allo-
geneic AML cells, both on allogeneic and
autochthonous AML targets. The results
showed that the maximum CMC against a
particular target cell depended upon that cell
being used to stimulate the patients lympho-
cytes in vitro, though such lymphocytes
showed varying degrees of cross-reactive
CMC on other allogeneic AML target cells.
The observation that maximum CMC occur-
red against the AML-stimulating cell was
consistent with the re-stimulation of specific
clones ofmemory cells by different AML cells.
However, no CMC had been detected against
autochthonous AML blasts, by stimulation of
patients lymphocytes in vitro with either
autochthonous or allogeneic AML cells.
Conversely, significant CMC was obtained
against PHA-transformed autochthonous
lymphocytes from normal individuals and
immunotherapy patients, following the induc-
tion of effector cells by one of the AML cells
used in these studies. Dr Taylor postulated
that the lack of CMC to autochthonous AML
blasts could be explained either by the
absence of tumour-specific antigens or the
inability of the CMC technique to detect
them. He postulated that further explana-
tion could be a lack of effector-to-target-cell
homology between lymphocytes and auto-
chthonous leukaemic blasts, caused by the
disturbance ofthe expression ofnormal HLA
antigens on the AML cells. Finally, he sug-
gested that some other genetic defect, pos-
sibly linked to the major histocompatibility
complex, might explain the inability to
demonstrate CMC to autochthonous leu-
kaemic blasts.
D. Crowther (Department of Medical
Oncology, Christie Hospital and Holt Radium
Institute, Manchester) reported studies in
cancer patients, involving tests for specific
microcytotoxicity, using autologous hyper-
nephroma cells and normal kidney cells in
short term culture. In addition, a variety of
cancer patients was tested for non-specific
leucocyte effector function. Direct cyto-
toxicity, PHA-induced cytotoxicity and anti-
body-dependent cell-mediated cytotoxicity
were measured using 51Cr release from Chang
target cells. There was no evidence of
specific cytotoxicity against hypernephroma
cells. Non-specific leucocyte effector func-
tion was depressed in certain groups ofcancer
patient beforetreatment (150patientstested).
This depression could be alleviated by partial
or complete tumour removal in the hyper-
nephroma system. In non-Hodgkin lym-
phoma patients, the depression in non-
specific cytotoxicity was related to pathology
and, to a lesser extent, stage of disease.
Patients with bladder and head and neck
tumours who responded to chemotherapy
using 5-fluorouracil and adriamycin, showed
an improvement in non-specific leucocyte
effector function, whereas non-responders
showed a deterioration. A series of normal
controls and untreated cancer patients with
advanced disease were given i.d. BCG
immunization and this was shown to improve
effector function ini leucocytes ofboth groups.
Thisincreaseinnon-specificcytotoxiccapacity
lasted to 3-4 weeks.
G. A. Currie (InstituteforCancerResearch,
Sutton, Surrey) stated that no in vitro assay
of tumour immunity to date had provided
information which was of prognostic value.
The only phenomenon which appeared to
correlate with biological behaviour of a
tumour was macrophage infiltration. In
experimental tumours and human malignant
melanoma, tumour macrophage content was
mirrored by levels of serum lysozyme.
Evaluation of macrophage function in cancer
patients had been hindered by uncertainties
in the identification of peripheral-blood
monocytes. Dr Currie suggested as an
operational definition, " those cells which
under standard conditions can differentiate
into a macrophage ", and described an assay
for macrophage precursor cells (MPC) based
on the enumeration of adherent cells present
in microplate wells 7 days after incubation of
Ficoll-triosil-separated mono-nuclear cells in
50% autologous serum. This assay had
revealed significant numerical differences
between cancer patients (predominantly those
with malignant melanoma) and normals, but
there was no apparent correlation between
MPC and tumour burden, nor with monocytes
identified morphologically inperipheral blood.
The differences observed between cancer
patients and normal subjects reflected innate
properties ofthe cellsratherthantheinfluence
of serum factors.
Three contributions were devoted to the
effects ofimmunological adjuvants in tumour
immunotherapy. In the first, M. V. Pimm
(Cancer Research Campaign Laboratories,
Nottingham University) showed that adju-
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vants can potentiate anti-tumour effector
mechanisms intwoways. Firstly, locally atthe
tumour site, adjuvants can prevent the
growth ofimmunogenic and, to alesserextent,
non-immunogenic tumours. This effect is
not dependent on a fully immunocompetent
host, and is achieved by local activation of
host macrophages. Thus BCG-induced inhi-
bition of xenografts of both rat and human
tumours (T24) in athymic nude mice could be
abrogated by administration ofsilica, a selec-
tive macrophage toxin. Secondly, addition
of adjuvants to attenuated tumour cells can
potentiate specific immune responses to
tumour-associated antigens (TAA) and lead
to concomitant destruction of tumour foci at
distant sites. This response is strictly depen-
dent on full immunocompetence and strong
TAA; embryonic antigens have todateproved
largely ineffective.
In the second contribution, K. James
(Department of Surgery, University of
Edinburgh Medical School) discussed the
nature and biological role of anti-tumour
antibodies in adjuvant-treated mice. Ad-
ministration of C. parvum to normal and
tumour-bearing mice results in the produc-
tion of " antibodies " which interact with
syngeneic and allogeneic tumour cells and
syngeneic embryonic fibroblasts in vitro, and
m#rkedly elevate the levels of IgG2a and
IgG2b. These serological changes can be
elicited in T-cell-deprived and nude mice, but
are inhibited by administration of gold salts.
Freshly excised tumour cells from adjuvant-
treated mice also have more Ig on their
surface thantumour cellsfromuntreatedmice.
The Ig exhibiting affinity for tumour cells is
heterogeneous in nature and can be absorbed
out with C. parvum and tumour. However,
incubation of tumour cells in sera from
adjuvant-treated mice has no detectable
influence on their growth following i.v. or s.c.
inoculation.
In the third paper of this series, R. Bom-
ford (Wellcome Research Laboratories, Kent)
discussed the problem ofgiving advice on the
clinical use of C. parvum on the basis of
experimental data which were frequently
inadequate. This was exemplified by two
situations in which treatment with C. parvum
promoted tumour growth: (i) development of
tumours in a proportion ofmice which receiv-
ed s.c. C. parvum before or shortly after a non-
tumourigenic dose of tumour cells and (ii)
abolition of tumour immunity in mice receiv-
ing i.v. C. parvum after being made specifi-
cally immune by tumour excision. Possible
interpretations of these phenomena included
modulation of specific immune responses,
generation of suppressor cells or more plaus-
ibly, lymphocyte trapping, a proven property
of C. parvum.
M. J. Embleton (Cancer Research Cam-
paign Laboratories, University of Notting-
ham) stated that, in addition to his previous
demonstration that cell-free tumour antigen
fractions inhibit the effector phase of the
immune response to TAA, similar prepara-
tions could also specifically depress the
induction of tumour immunity. Thus, prior
administration of extranuclear tumour mem-
brane or 3M-KCl-solubilized extracts of anti-
genic chemically-induced rat sarcomas, ren-
dered the hosts incapable ofdeveloping trans-
plantation resistance after immunization
with irradiated tumour grafts, although
humoral antibody formation was unaffected.
Impairment of cellular immunity correlated
with the presence oftumour antigen-antibody
complexes in serum, and a population of
suppressor cells which inhibit cytotoxicity by
sensitized lymphoid cells in vitro. Such a
phenomenon could be implicated in escape
from immunosurveillance, since many tu-
mours are known to release soluble antigen
into the circulation from the early stages of
their establishment.
R. A. Robins (Cancer Research Campaign
Laboratories, University of Nottingham) dis-
cussedthenature ofserumfactorswhich inter-
fere in vitro with cell-mediated cytotoxic
reactions against rat hepatoma and sarcoma,
and their possible role in vivo. Abrogation of
immune-lymph-node cell cytotoxicity by
serum from tumour-bearing rats was inter-
preted as blocking activity by immune com-
plexes of tumour-specific antibody and
soluble tumour antigen. Experiments with
artificial complexes showed that the balance
between antigen and antibody was critical for
blocking at the level of the target cell, but
tha.t excess tumour antigen could inhibit
effector-cell cytotoxicity. This indicates the
importance of the antigen moiety, either free
or in immune complexes, in the abrogation of
cell-mediated cytotoxicity in vitro.
Dr Robins then described investigations
into abrogation of tumour immunity in vivo.
Rats injected with a mixture ofviable tumour
cells and BCG have been shown to reject a
contralateral inoculum of viable tumour cells
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given at the same time. I.p. injection of
soluble tumour antigen preparations was
shown to abrogate the rejection ofthis viable
contralateral tumour challenge. This effect
was dose dependent and tumour specific.
Abrogation of immunotherapy has also been
obtained with irradiated tumour cells, with
serum from tumour-antigen-treated rats and
with serum from irradiated rats bearing
tumours, but serum from normal rats bearing
tumours has so far been ineffective. Abroga-
tion of tumour rejection is probably not due
to interference with the development of cell-
mediated immunity, as cell-mediated cyto-
toxicity could be detected inimmunotherapy-
treated rats whether ornotthey were injected
with tumour antigen.
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